Glucotrack Announces Publication of Peer-Reviewed Study Supporting Long-Life Sensor Design for Implantable Continuous Blood Glucose Monitoring Technology

Glucotrack (Nasdaq: GCTK) announced a peer‑reviewed publication in IEEE Sensors Journal (published April 7, 2026) reporting the first year‑long in‑vitro measurement of glucose oxidase deactivation in electrochemical sensors.

Rhea-AI Summary

Glucotrack (Nasdaq: GCTK) announced a peer‑reviewed publication in IEEE Sensors Journal (published April 7, 2026) reporting the first year‑long in‑vitro measurement of glucose oxidase deactivation in electrochemical sensors.

The study, done with TTP (UK), examined sensors built to mimic ~two‑year‑old devices and supports the feasibility of long‑life implantable continuous blood glucose monitoring. Glucotrack cited prior first‑in‑human results (MARD 7.7%, 99% data capture) and said the work supports near‑term IDE submission efforts.

Positive

• Peer‑reviewed publication in IEEE Sensors Journal (April 7, 2026)
• First year‑long in‑vitro measurement of glucose oxidase deactivation reported
• Study partnered with TTP, a UK scientific and engineering organization
• Previous human data: MARD 7.7% and 99% data capture with no serious adverse events

Negative

• Study was in‑vitro rather than a new in‑human clinical trial
• IDE not yet submitted; company is working toward submission in the near term

Argus Apr 21 session

-3.97% close to close Open Argus

Details

News Market Reaction – GCTK

On Apr 21, the day this news came out, GCTK closed 3.97% below the previous close.

Data tracked by StockTitan Argus for the Apr 21 session.

Market Context

This announcement reinforces the technical underpinnings of Glucotrack’s fully implantable CBGM by a...

Analysis

This announcement reinforces the technical underpinnings of Glucotrack’s fully implantable CBGM by adding a year‑long glucose oxidase stability study to earlier first‑in‑human data showing MARD of 7.7% and 99% data capture. Historically, the company paired such milestones with capital raises and an effective S-3 registering 3,224,803 resale shares, alongside a $19.4M 2025 net loss and going‑concern language. Investors may watch future IDE submission timing, clinical results, and potential use of registered shares as key signals.

Key Figures

Study duration: 1 year Intended device age: 2 years MARD: 7.7% +4 more

Study duration

1 year

Year-long in-vitro glucose oxidase stability characterization

Intended device age

2 years

Sensors constructed to reflect approximately two year old devices

MARD

7.7%

First-in-human clinical results for CBGM

Data capture rate

99%

First-in-human CBGM study data capture

Brazil study size

10 patients

First-in-human clinical trial in Brazil

Brazil study length

5 days

Brazil first-in-human CBGM study duration

IEEE membership

486,000 professionals

Global IEEE organization size mentioned for journal context

Historical Context

5 past events · Latest: Mar 30

5 events

1. Mar 30

   Earnings & update

   24h Move

   -14.1%

   Reported 2025 results, cash of $7.4M, and IDE plan for Q2 2026.

2. Mar 27

   IDE trial plans

   24h Move

   -9.2%

   Outlined IDE filing in Q2 2026 and U.S. trial start in H2 2026.

3. Mar 10

   Conference appearance

   24h Move

   -2.4%

   Announced LSI USA ’26 presentation on CBGM technology and plans.

4. Jan 29

   Patent issuances

   24h Move

   -33.4%

   Announced three USPTO patents covering CBGM chemistry and hardware.

5. Dec 30

   Private placement

   24h Move

   -10.8%

   Priced $4.0M private placement with shares and 2,067,182 warrants.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

in-vitro, electrochemical glucose sensors, glucose oxidase, continuous blood glucose monitoring, +4 more

8 terms

in-vitro medical

"Year-long in-vitro characterization of glucose oxidase stability supports the feasibility"

In-vitro means a laboratory test or experiment done outside a living organism, typically in a test tube, petri dish, or similar container. For investors, in-vitro results are early-stage evidence that a compound or process can work under controlled lab conditions; they can spark interest and influence valuation but carry higher uncertainty because success in a dish does not guarantee safety or effectiveness in people.

electrochemical glucose sensors medical

"characterizing the long-term in-vitro stability of electrochemical glucose sensors"

Electrochemical glucose sensors are medical devices that measure the amount of sugar in blood or interstitial fluid by producing a tiny electrical signal when glucose reacts with a chemical on the sensor—think of it as a fuel gauge that converts sugar into a readable number. Investors care because these sensors drive recurring sales (consumable strips or sensors), depend on regulatory approvals and reimbursement, and their accuracy and ease of use directly affect market adoption and revenue growth.

glucose oxidase medical

"measurement of glucose oxidase enzyme decay reported in the literature"

An enzyme that reacts with glucose to produce hydrogen peroxide and a small electrical or color change, making blood sugar levels measurable. Think of it as the tiny detector inside many glucose test strips and biosensors that turns sugar into a readable signal. Investors care because its performance, supply and regulatory approval directly affect companies that make diabetes tests, point‑of‑care devices, certain food processing steps and related biotech products.

continuous blood glucose monitoring medical

"the Company’s fully implantable continuous blood glucose monitoring (CBGM) system"

A continuous blood glucose monitoring system is a wearable sensor and accompanying device or app that measures a person’s blood-sugar level frequently throughout the day and night, sending real-time readings and alerts for highs or lows. For investors, these systems matter because they can drive steady product sales, recurring data or service revenue, and influence healthcare costs and treatment choices the same way a smart thermostat changes heating habits—wider adoption can reshape the market for diabetes care.

cbgm medical

"Glucotrack’s CBGM, over a one-year period"

Capillary blood glucose monitoring (CBGM) is the common finger‑stick method that measures blood sugar from a tiny drop of capillary blood using a portable meter and test strip. For investors, CBGM matters because it drives demand, regulation and reimbursement in the diabetes device market—accuracy, cost and convenience determine which products succeed, much like fuel efficiency and price steer car buyers.

investigational device exemption regulatory

"submission of our IDE with the FDA in the near term"

An investigational device exemption (IDE) is a regulatory permission that allows a medical device maker to test an unapproved device in people so the device’s safety and effectiveness can be studied. For investors, an IDE matters because it marks a formal step toward regulatory approval—like getting a temporary test-drive permit—and influences clinical cost, timelines, and the likelihood a device will reach the market and generate revenue.

ide regulatory

"work towards the submission of our IDE with the FDA in the near term"

An IDE (Investigational Device Exemption) is a regulatory permission that allows a company to test an unapproved medical device in human clinical trials to gather safety and effectiveness data. Think of it as a temporary road permit for a new product: getting the IDE moves a technology from concept toward approval and market access, which can reduce uncertainty and increase value for investors, while delays or denials raise development risk and potential costs.

mean absolute relative difference medical

"first-in-human clinical results demonstrating a highly-accurate MARD of 7.7%"

Mean absolute relative difference (MARD) is the average of the absolute percent differences between predicted and actual values, calculated by taking the absolute value of each forecast error divided by the actual value and then averaging those percentages. For investors it measures how far forecasts, model outputs or quoted prices typically stray from reality, acting like an average ‘percent-off’ score that helps compare and trust different forecasts or data sources—similar to averaging how much multiple recipes’ portions differ from the intended serving size.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Year-long in-vitro characterization of glucose oxidase stability supports the feasibility of long-life implantable continuous glucose monitors, independent third party review of the longevity and functionality of design in the latter stage of in-human use

RUTHERFORD, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced the publication of a peer-reviewed scientific article in the Institute of Electrical and Electronics Engineers (IEEE) Sensors Journal characterizing the long-term in-vitro stability of electrochemical glucose sensors of the type used in the Company’s fully implantable continuous blood glucose monitoring (CBGM) system. The findings represent the first year-long measurement of glucose oxidase enzyme decay reported in the literature and support the feasibility of long-life implantable continuous glucose monitors.

The publication, titled “Year-Long Measurement of Glucose Oxidase Deactivation in Electrochemical Glucose Sensors,” (Ernst, S. et al.), examined the long-term in-vitro performance and stability of an electrochemical glucose sensor based on glucose oxidase, the enzyme class used in Glucotrack’s CBGM, over a one-year period.

The objective of the study was to assess sensor performance during the final year of its intended functional life. Accordingly, sensors used in the study were constructed to reflect approximately two year old devices. The findings represent the first year-long measurement of glucose oxidase enzyme decay, providing higher-confidence in the design of our long-life implantable glucose sensor.

Glucotrack partnered with TTP, a United Kingdom‑based scientific and engineering organization with experience supporting life sciences and medical device innovation, for this study and publication. The article was published on April 7, 2026 in the highly regarded technical journal, the IEEE Sensors Journal, part of the Institute of Electrical and Electronics Engineers, a global organization of over 486,000 leading STEM professionals worldwide, and is available online here.

“This work provides externally reviewed scientific evidence relevant to the design of long-life implantable glucose sensors. Peer-reviewed characterization of foundational sensor data is an important step as we continue to advance our development program and work toward clinical and regulatory milestones,” commented Dr. Paul Goode, President and Chief Executive Officer of Glucotrack.

“TTP has a strong reputation in our space, and we had a very positive experience working with their team. We anticipate that this article, among other similar projects we have in process, should serve our team well as we work towards the submission of our IDE with the FDA in the near term,” concluded Dr. Goode.

This publication is one part of Glucotrack’s ongoing effort to build a transparent, peer-reviewed technical foundation for the development of its CBGM technology. Glucotrack previously reported first-in-human clinical results demonstrating a highly-accurate MARD of 7.7% and a 99% data capture rate, with no procedure- or device-related serious adverse events.

For more information about Glucotrack's CBGM, visit www.glucotrack.com.

About Glucotrack, Inc.

Glucotrack, Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently developing a long-term implantable continuous blood glucose monitoring system for people living with diabetes.

Glucotrack’s Continuous Blood Glucose Monitor (CBGM) is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. The Glucotrack CBGM is an Investigational Device and is limited by federal (or United States) law to investigational use.

For more information, please visit http://www.glucotrack.com. Information on the Company’s website does not constitute a part of and is not incorporated by reference into this press release.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “anticipate”, “believe”, “expect”, “plan” and “will” are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, management. These statements relate only to events as of the date on which the statements are made, and Glucotrack undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. All of the forward-looking statements made in this press release are qualified by these cautionary statements, and there can be no assurance that the actual results anticipated by Glucotrack will be realized or, even if substantially realized, that they will have the expected consequences to or effects on us or our business or operations. Readers are cautioned that certain important factors may affect Glucotrack’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Glucotrack’s results include, but are not limited to, the ability of Glucotrack to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to the receipt (and timing) of regulatory approvals (including U.S. Food and Drug Administration approval); risks relating to enrollment of patients in, and the conduct of, clinical trials; risks relating to Glucotrack’s future distribution agreements; risks relating to its ability to hire and retain qualified personnel, including sales and distribution personnel; and the additional risk factors described in Glucotrack’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10-K for the year ended December 31, 2025 as filed with the SEC on March 30, 2026.

Contacts:
Investor Relations:	Media:
investors@glucotrack.com	GlucotrackPR@icrinc.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Glucotrack (GCTK) publish on April 7, 2026 in IEEE Sensors Journal?

Glucotrack published a peer‑reviewed study reporting year‑long in‑vitro glucose oxidase decay measurements. According to Glucotrack, the article characterizes long‑term sensor stability relevant to long‑life implantable CBGM designs.

How does the published study affect Glucotrack's implantable continuous glucose monitor (GCTK)?

The study supports the feasibility of long‑life implantable CBGM by measuring enzyme decay over one year. According to Glucotrack, sensors were built to reflect ~two‑year‑old devices to assess final functional life performance.

Who collaborated with Glucotrack on the sensor stability study for GCTK?

Glucotrack partnered with TTP, a UK scientific and engineering organization, for study execution and review. According to Glucotrack, TTP has experience supporting life sciences and medical device innovation.

What clinical performance has Glucotrack previously reported for its CBGM (GCTK)?

Glucotrack previously reported first‑in‑human results with a MARD of 7.7% and 99% data capture rate. According to Glucotrack, there were no procedure‑ or device‑related serious adverse events.

Will Glucotrack (GCTK) file an IDE with the FDA based on this publication?

Glucotrack is working toward submitting an IDE in the near term but has not filed yet. According to Glucotrack, the peer‑reviewed data should support progress toward clinical and regulatory milestones.